ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease
Gastroesophageal reflux disease (GERD) continues to be among the most common
diseases seen by gastroenterologists, surgeons, and primary care physicians. Our …
diseases seen by gastroenterologists, surgeons, and primary care physicians. Our …
Umbrella review of 42 systematic reviews with meta‐analyses: the safety of proton pump inhibitors
EM Salvo, NC Ferko, SB Cash… - Alimentary …, 2021 - Wiley Online Library
Summary Background Proton pump inhibitors (PPIs) are widely used to treat and prevent
acid‐related disorders. Despite high efficacy, PPI safety has been increasingly scrutinised …
acid‐related disorders. Despite high efficacy, PPI safety has been increasingly scrutinised …
[HTML][HTML] Adverse effects associated with long-term use of proton pump inhibitors
NMP Maideen - Chonnam medical journal, 2023 - ncbi.nlm.nih.gov
Abstract Proton Pump Inhibitors are used widely to manage many gastric acid-related
conditions such as gastroesophageal disease, gastritis, esophagitis, Barrett's esophagus …
conditions such as gastroesophageal disease, gastritis, esophagitis, Barrett's esophagus …
An update on drug–drug interactions associated with proton pump inhibitors
I Ben Ghezala, M Luu, M Bardou - Expert Opinion on Drug …, 2022 - Taylor & Francis
ABSTRACT Introduction Proton pump inhibitors (PPIs) block the gastric H/K-ATPase,
therefore inhibiting acid gastric secretion, leading to an increased pH (> 4). They account for …
therefore inhibiting acid gastric secretion, leading to an increased pH (> 4). They account for …
Does the long-term administration of proton pump inhibitors increase the risk of adverse cardiovascular outcomes? A ChatGPT powered umbrella review
E Teperikidis, A Boulmpou, V Potoupni, S Kundu… - Acta …, 2023 - Taylor & Francis
Abstract Background Proton pump inhibitors (PPIs) are commonly prescribed for the
treatment of acid-related disorders. In the context of coronary artery disease (CAD), PPIs are …
treatment of acid-related disorders. In the context of coronary artery disease (CAD), PPIs are …
Chinese expert consensus on gastroesophageal reflux disease in 2020.
YL Xiao, LY Zhou, XH Hou, YQ Li… - Journal of Digestive …, 2021 - search.ebscohost.com
A meta-analysis of 1437 patients from 14 RCTs in China showed that prokinetics combined
with PPI were more effective in alleviating symptoms than PPI monotherapy; however, no …
with PPI were more effective in alleviating symptoms than PPI monotherapy; however, no …
Proton pump inhibitors and the risk of cardiovascular events and cardiovascular mortality: a systematic review and meta-analysis of observational studies
Abstract Background and Aims Observational research has indicated that proton pump
inhibitors (PPIs) might increase the long-term risk of cardiovascular events. This study …
inhibitors (PPIs) might increase the long-term risk of cardiovascular events. This study …
Proton pump inhibitor use and risks of cardiovascular disease and mortality in patients with type 2 diabetes
T Geng, JX Chen, YF Zhou, Q Lu, Z Wan… - The Journal of …, 2023 - academic.oup.com
Abstract Context Proton pump inhibitors (PPIs) are widely used drugs for gastric acid–
related diseases and may affect the gut microbiome. Objective We aimed to evaluate the …
related diseases and may affect the gut microbiome. Objective We aimed to evaluate the …
The long‐term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008‐2018)
Summary Background Proton pump inhibitors (PPIs) are well tolerated in the short term but
have recently been associated with increased long‐term cardiovascular risk in observational …
have recently been associated with increased long‐term cardiovascular risk in observational …
Association of proton pump inhibitor use with endothelial function and metabolites of the nitric oxide pathway: A cross‐sectional study
Abstract Study Objective Long‐term intake of proton pump inhibitors (PPIs) might increase
the risk of cardiovascular events. One suggested mechanism is that PPIs inhibit the enzyme …
the risk of cardiovascular events. One suggested mechanism is that PPIs inhibit the enzyme …